Instruction for use: Buserelin

ATX Code L02AE01 Buserelin

Pharmacological group

An antineoplastic agent analogous to gonadotropin-releasing hormone [Hormones of the hypothalamus, pituitary gland, gonadotropins and their antagonists]

An antineoplastic agent analogous to gonadotropin-releasing hormone [Antitumor hormonal agents and hormone antagonists]

Nosological classification (ICD-10)

D25 Leiomyoma of the uterus

Fibroids of the uterus

D26 Other benign neoplasms of the uterus

Fibromyoma of the uterus, Myoma, Uterine fibroids, Fibromyoma, Myoma of the uterus, Fibrrios, Meigs syndrome, Tumors of the uterus

E28.0 Excess of estrogens

Hyperestrogenism, Absolute hyperestrogenism, Hyperestrogenism

N80 Endometriosis

Endometrioid endometriosis

N85.0 Endometrial glandular hyperplasia

Hyperplastic processes of the endometrium, Cystic glandular hyperplasia of the endometrium

N85.1 Adenomatous endometrial hyperplasia

N97 Female infertility

Female infertility in anovulation, Hyperprolactinemic infertility, Hyperprolactinaemia with infertility, Endocrine infertility, Infertility due to hypothalamic-pituitary dysfunction, Infertility infertility, Infertility, Infertility on the background of hyperprolactinaemia, Functional infertility, Marriage is infertile, Infertility of ovarian genesis, Stimulation of the growth of a single follicle

Z31.2 In Vitro Fertilization

Support of the luteal phase in the spontaneous or induced menstrual cycle, Support of the luteal phase during preparation for in vitro fertilization, Reproductive technologies, Superovulation, ECO, In Vitro Fertilization, Controlled superovulation in in vitro fertilization

Composition

Spray nasal dosed

active substance:

Buserelina acetate 2,100 mg

(Corresponds to a content of 2,000 mg buserelin)

Excipients:

Benzalkonium chloride 0.100 mg

Water for injection up to 1 ml

pharmachologic effect

Pharmacological action - antiandrogenic, antigonadotropic, antiestrogenic.

Dosing and Administration

A single dose of the drug when the pump is fully depressed is 150 μg.

In the treatment of endometriosis, uterine fibroids, endometrial hyperplastic processes: the drug is injected into the nasal passages after their purification at a dose of 900 mcg / day. The daily dose of the drug is given in equal portions, one injection at each nasal passage 3 times a day at regular intervals (6-8 hours) in the morning, afternoon and evening. Treatment with Buselelin should be started on the first or second day of the menstrual cycle, the introduction is continuous throughout the course of treatment. The course of treatment is 4-6 months.

In the treatment of infertility by extracorporeal fertilization (IVF): Buserelin spray is administered intranasally on a single injection (150 μg) in each nostril 3-4 times a day at regular intervals. The daily dose of 900-1200 mcg. Buserelin is prescribed at the beginning of the follicular (on the 2nd day of the menstrual cycle) or in the middle of the luteal phase (21-24 days) of the menstrual cycle preceding stimulation. After 14-17 days with a decrease in estradiol in the serum of patients, no less than 50% of the baseline level, absence of cysts in the ovaries, and an endometrium thickness of not more than 5 mm begin stimulation of superovulation by gonadotropic hormones under ultrasound monitoring and control of serum estradiol levels. If necessary, dose adjustment may be carried out by Buserelin.

Form of issue

Spray nasal dosed with 0.15 mg / dose. At 17.5 ml (not less than 187 doses) of the drug in bottles of orange glass grade HC-1, sealed with plastic caps screwed on with the control ring of the first opening. On 1 fl. Complete with a dosing plastic stopper pomp placed in a cardboard box.

Terms of leave from pharmacies

On prescription.

storage Conditions

In the dark place at a temperature of 8 to 25 ° C.

Keep out of the reach of children.

Shelf life

3 years.

Do not use after the expiry date printed on the package.